Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies-Reference-Cited by-同舟云学术

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

Published:2016-08-29 Issue:10 Volume:126 Page:3814-3826
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Ruella Marco^ORCID,Barrett David M.,Kenderian Saad S.^ORCID,Shestova Olga,Hofmann Ted J.,Perazzelli Jessica,Klichinsky Michael,Aikawa Vania,Nazimuddin Farzana,Kozlowski Miroslaw,Scholler John,Lacey Simon F.,Melenhorst Jan J.,Morrissette Jennifer J.D.,Christian David A.,Hunter Christopher A.,Kalos Michael,Porter David L.,June Carl H.,Grupp Stephan A.,Gill Saar

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/87366/files/pdf

Reference65 articles.

1. Modern Therapy of Acute Lymphoblastic Leukemia

2. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study;Fielding;Blood,2007

3. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial;Tavernier;Leukemia,2007

4. Relapsed childhood acute lymphoblastic leukaemia

5. Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Cited by 469 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

2. Bispecific antibodies: advancing precision oncology;Trends in Cancer;2024-08

3. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells;Cellular Oncology;2024-07-15

4. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model;Blood;2024-07-11

5. Augmenting the landscape of chimeric antigen receptor T-cell therapy;Expert Review of Anticancer Therapy;2024-06-26